Zephyr AI

Incubation Healthcare 2021

Better Outcomes for a Brighter Future

“The expansion of our diverse multimodal data resources will accelerate the advancement of our algorithms and pave the way for us to transform the landscape of precision medicine and improve outcomes for our patients and partners.”
Jeff Sherman Co-Founder, Interim CEO, and CTO, Zephyr AI

Company Type:
Incubation

Founded:
2021

Stage:
Series A

Red Cell Phase:
Growth

Practice Area:
Healthcare

zephyrai.bio

The Problem

Among high-income countries, the United States boasts the highest rate of avoidable cancer and cardiometabolic-related deaths. Combined with escalating healthcare costs, slow drug development protocols, and high failure rates for clinical trials, meaningful improvement in patient outcomes has stalled. We need new drugs, better biomarkers for existing drugs, and better decision-support tools to appropriately manage patient outcomes, particularly those living with cancer and cardiometabolic disease.

The Solution

Zephyr AI is a healthcare technology company committed to radically reshaping precision medicine in the areas of oncology and cardiometabolic disease. Through strategic partnerships and proprietary data, Zephyr is curating one of the world’s largest, most comprehensive healthcare datasets and marrying it with cutting-edge artificial intelligence algorithms to expedite the launch of new drugs into the market, uncover expanded applications for existing therapies, and improve outcomes for patients.

“At Zephyr, we are harnessing the power of AI to extract novel insights to better define patient stratification and response predictions as well as improve federation of real-world data…We are deploying one of the world’s largest clinicogenomic datasets boasting unprecedented breadth across disease states and data partners. Collectively, we are now well-positioned to support our mission of democratizing precision medicine, enhancing both the speed and success of clinical trials.”
Grant Verstandig Founder, Chairman, & CEO, Red Cell Partners